Premium
Mesalazine granules 1.5 g once‐daily maintain remission in patients with ulcerative colitis who switch from other 5‐ ASA formulations: a pooled analysis from two randomised controlled trials
Author(s) -
Lichtenstein G. R.,
Zakko S.,
Gordon G. L.,
Murthy U.,
Sedghi S.,
Pruitt R.,
Merchant K.,
Bortey E.,
Forbes W. P.
Publication year - 2012
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.2012.05142.x
Subject(s) - mesalazine , medicine , placebo , ulcerative colitis , gastroenterology , maintenance therapy , clinical endpoint , intention to treat analysis , placebo controlled study , randomized controlled trial , aminosalicylic acid , surgery , chemotherapy , disease , double blind , pathology , alternative medicine
Summary Background Mesalazine (mesalamine) granules ( MG ) were shown to be effective for the maintenance of remission of ulcerative colitis ( UC ) in two double‐blind placebo‐controlled trials. Aim To evaluate the efficacy of once‐daily MG for maintenance of remission in patients with UC who switched from other 5‐aminosalicylic acid (5‐ ASA ) formulations. Methods Data from two independent multicenter, randomised, double‐blind, placebo‐controlled, 6‐month trials evaluating patients with UC in remission were combined for analysis of a subpopulation of patients who switched from other 5‐ ASA formulations to MG 1.5 g or placebo upon randomisation. The primary endpoint was the percentage of patients who remained relapse‐free at Month 6 or end of treatment. Relapse was defined as a Sutherland Disease Activity Index ( SDAI ) rectal bleeding score ≥1 and mucosal appearance score ≥2, a UC flare or medication used to treat a UC flare. Results Of the 487 patients who received 5‐ ASA maintenance therapy at enrolment, 322 were in the MG group and 165 were in the placebo group. The percentage of patients who remained relapse‐free (based on Sutherland Disease Activity Index scores) after 6 months was significantly higher with MG than placebo (78.3% vs. 58.8%, P < 0.001). Rectal bleeding, stool frequency and the physician's rating of disease activity remained unchanged after 6 months in a higher percentage of patients using MG compared with those on placebo ( P < 0.004 for each endpoint). Conclusion Mesalazine granules 1.5 g once‐daily is effective for maintenance of remission in UC patients who switch from other 5‐ ASA formulations. ClinicalTrials.gov identifiers NCT 00744016, NCT 00767728.